...
首页> 外文期刊>BMC Urology >Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis
【24h】

Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis

机译:比较部分肾切除术和根治性肾切除术对4 cm至7 cm肾细胞癌的长期随访和围手术期结果:系统评价和荟萃分析

获取原文
           

摘要

The efficacy of partial nephrectomy (PN) for T1b renal cell carcinoma (RCC) is controversial. The oncological outcomes, the change in postoperative renal function and the perioperative complications are unclear. We searched PUBMED, EMBASE and the Cochrane Central Register for studies from March 1998 to March 2018 for studies comparing PN to radical nephrectomy (RN) for the treatment of T1b RCC. After data extraction and quality assessment, we used RevMan 5.2 to pool the data. Then, we used Stata 12.0 to perform sensitivity analyses and meta-regression. We used the GRADE profiler to evaluate the evidence according to the GRADE approach. A total of 16 studies involving 33,117 patients were included in our meta-analysis. No significant difference was found in the 5-year overall survival (OS), 10-year OS, 5-year recurrence-free survival (RFS) and 10-year RFS. The 5-year cancer-special survival (CSS) and 10-year CSS were better in RN compared to PN, respectively, at RR?=?1.02, P??0.05 and RR?=?1.04, P??0.05. PN was better than RN in the preservation of renal function (WMD?=?-9.15, 95% CI: ??10.30 to ??7.99, P??0.05). The confidence level grading of the evidence was moderate for 5-year OS, 10-year OS, 5-year CSS, 10-year CSS, 5-year RFS, 10-year RFS, tumor recurrence, decline in eGFR, and postoperative complications. PN may provide comparable outcomes in terms of RFS & OS, and better renal function preservation although CSS was worse.
机译:肾部分切除术(PN)对T1b肾细胞癌(RCC)的疗效存在争议。尚不清楚肿瘤的结局,术后肾功能的变化和围手术期并发症。我们搜索了PUBMED,EMBASE和Cochrane Central Register从1998年3月至2018年3月进行的研究,以比较PN与根治性肾切除术(RN)来治疗T1b RCC。在数据提取和质量评估之后,我们使用RevMan 5.2合并数据。然后,我们使用Stata 12.0进行敏感性分析和元回归。我们使用GRADE分析器根据GRADE方法评估证据。我们的荟萃分析共包括16项研究,涉及33,117例患者。在5年总生存期(OS),10年OS,5年无复发生存期(RFS)和10年RFS中没有发现显着差异。与PN相比,RN的5年癌症特殊生存率(CSS)和10年CSS更好,分别为RR <= 1.02,P 0.05,RR <= 1.04,P 0.05 。在保持肾功能方面,PN优于RN(WMD≥= -9.15,95%CI:≥10.30至≥7.99,P <0.05)。对于5年OS,10年OS,5年CSS,10年CSS,5年RFS,10年RFS,肿瘤复发,eGFR下降和术后并发症,证据的置信度等级为中等。 。 PN可能在RFS和OS方面提供可比的结果,并且尽管CSS较差,但可以更好地保留肾脏功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号